Resumen
Background The Initiating Dialysis Early and Late (IDEAL) trial, published in 2009, found no clinically measurable benefit with respect to risk of mortality or early complications with early dialysis initiation versus deferred dialysis start. After these findings, guidelines recommended an intent-to-defer approach to dialysis initiation, with the goal of deferring it until clinical symptoms arise. Methods To evaluate a four-component knowledge translation intervention aimed at promoting an intent-to-defer strategy for dialysis initiation, we conducted a cluster randomized trial in Canada between October 2014 and November 2015. We randomized 55 clinics, 27 to the intervention group and 28 to the control group. The educational intervention, using knowledge-translation tools, included telephone surveys from a knowledge-translation broker, a 1-year center-specific audit with feedback, delivery of a guidelines package, and an academic detailing visit. Participants included adults who had at least 3 months of predialysis care and who started dialysis in the first year after the intervention. The primary efficacy outcome was the proportion of patients who initiated dialysis early (at eGFR.10.5 ml/min per 1.73 m2). The secondary outcome was the proportion of patients who initiated in the acute inpatient setting. Results The analysis included 3424 patients initiating dialysis in the 1-year follow-up period. Of these, 509 of 1592 (32.0%) in the intervention arm and 605 of 1832 (33.0%) in the control arm started dialysis early. There was no difference in the proportion of individuals initiating dialysis early or in the proportion of individuals initiating dialysis as an acute inpatient. Conclusions A multifaceted knowledge translation intervention failed to reduce the proportion of early dialysis starts in patients with CKD followed in multidisciplinary clinics.
Idioma original | English |
---|---|
Páginas (desde-hasta) | 1791-1800 |
Número de páginas | 10 |
Publicación | Journal of the American Society of Nephrology : JASN |
Volumen | 32 |
N.º | 7 |
DOI | |
Estado | Published - jul. 2021 |
Nota bibliográfica
Funding Information:A. Alam reports receiving honoraria from AstraZeneca, Janssen, Novo Nordisk, and Otsuka Pharmaceutical; reports having consultancy agreements with AstraZeneca, Bayer, Janssen Canada, Otsuka Canada; reports speakers bureau from Janssen Canada and Otsuka Canada; and other interests/relationships with Royal College International (Canada). A. Garg reports receiving partnership grant funding from Astellas Canada Inc. for a Canadian Institutes of Health Research funded grant in living kidney donation; reports being a scientific advisor to or member of the Editorial Board of Kidney International and American Journal of Kidney Diseases; and reports other interests/relationships as member of the Data Safety and Monitoring Board for an Investigator Initiated Trial Program Funded by GlaxoSmithKline, Medical Lead Role to Improve Access to Kidney Transplantation and Living Kidney Donation for the Ontario Renal Network (government funded agency located within Ontario Health). C. Rigatto reports consultancy agreements with AstraZeneca, Boehringer Ingelheim, Lilly, and Sanofi; reports receiving research funding from Sanofi; reports receiving honoraria from Boehringer Ingelheim, Lilly, and Sanofi; reports being a scientific advisor or member of the Canadian Journal of Kidney Health and Disease. G. Nesrallah reports receiving consulting fees from Amgen Inc. and Baxter Healthcare; reports consultancy agreements with AstraZeneca, Baxter Healthcare, and Otsuka; and reports receiving research funding from Baxter Healthcare. M. Sood has received educational funds from AstraZeneca and reports being a scientific advisor or member of the Editorial Board of CJASN, Editorial Board of American Journal of Kidney Disease, Editorial Board of Canadian Journal of Cardiology, Editor of Canadian Journal of Kidney Disease and Health, and Member of the ASN Highlights ESKD Team. N. Tangri reports receiving honoraria from AstraZeneca, Bayer, BI-Lilly, Boehringer Ingelheim Canada Ltd., Janssen, Otsuka Pharmaceutical, Pfizer, and Tricida Inc.; and has received research support from AstraZeneca Inc., Janssen, Otsuka and Tricida Inc.; reports consultancy agreements with Mesentech Inc., PulseData Inc., Renibus, and Tricida Inc.; ownership interest in Clinpredict Ltd., Mesentech Inc., PulseData Inc, Renibus, Tricida Inc.; and reports being a scientific advisor or member of Mesentech, Pulsedata Inc., Renibus, and Tricida Inc. P. Komenda reports receiving honoraria from AstraZeneca, Boehringer Ingel-heim Canada, and Otsuka Pharmaceutical; reports being a member of the scientific advisory board for NxStage Medical Inc. and is the consultant Chief Medical Officer for Quanta Dialysis Technologies; reports consultancy agreements as Chief Medical Officer of Quanta Dialysis Technologies; reports an ownership interest in Quanta Dialysis Technologies; reports receiving research funding from AstraZeneca, Baxter, and NxStage; reports receiving honoraria from AstraZeneca, Boehringer Ingelheim, Janssen, Otsuka, and Quanta; and reports other interests/relationships with Chronic Disease Innovation Centre, Canadian Society of Nephrology Executive, and Seven Oaks Hospital Foundation Council. S. Kim has received support from Astellas Pharma Canada; and reports being a scientific advisor or member of Canadian Blood Services, Canadian Society of Transplantation, CORR, Health Canada, Scientific Registry of Transplant Recipients Technical Advisory Committee, and Organ Procurement and Transplantation Network/United Network for Organ Sharing Data Advisory Committee; and reports other interests/relationships through being Steering Committee member for the Canadian Transplant Forum (cosponsored by Astellas Pharma, Pfizer, and Alexion). S. Soroka reports receiving honoraria from AstraZeneca, Bayer, and Otsuka; and reports speakers bureau from AstraZeneca, Bayer, Jannsen, and Otsuka. T. Ferguson reports consultancy agreements with Clinpredict, Navdeep Tan-gri Medical Corporation, Quanta Dialysis Technologies, and Strategic Health Resources. All remaining authors have nothing to disclose.
Publisher Copyright:
© 2021 by the American Society of Nephrology
ASJC Scopus Subject Areas
- Nephrology
PubMed: MeSH publication types
- Journal Article